Home Cart Sign in  
Chemical Structure| 2248666-66-0 Chemical Structure| 2248666-66-0

Structure of PF429242 2HCl
CAS No.: 2248666-66-0

Chemical Structure| 2248666-66-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PF429242 2HCl is a reversible and competitive SREBP site 1 protease (S1P) inhibitor with IC50 value of 175nM.

Synonyms: PF-429242 (hydrochloride); PF429242 dihydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PF429242 2HCl

CAS No. :2248666-66-0
Formula : C25H37Cl2N3O2
M.W : 482.49
SMILES Code : O=C(N(CCC1=CC=CC=C1OC)[C@H]2CNCC2)C3=CC=C(CN(CC)CC)C=C3.[H]Cl.[H]Cl
Synonyms :
PF-429242 (hydrochloride); PF429242 dihydrochloride
MDL No. :MFCD22683795
InChI Key :GSUZWFZKTIOWTI-MQWQBNKOSA-N
Pubchem ID :90488837

Safety of PF429242 2HCl

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H372-H410
Precautionary Statements:P501-P273-P260-P270-P264-P280-P391-P314-P337+P313-P305+P351+P338-P301+P312+P330
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

Description
PF429242 dihydrochloride is a reversible and competitive inhibitor of SREBP site 1 protease (S1P) with an IC50 of 175 nM[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 20 µM 24 hours PF-429242 induced autophagy-dependent cell death Am J Cancer Res. 2023 Sep 15;13(9):4125-4144
PLC5 cells 20 µM 24 hours PF-429242 induced autophagy-dependent cell death Am J Cancer Res. 2023 Sep 15;13(9):4125-4144
HAP1 cells 0.95 µM (EC50) 3 days Inhibits EBOV-ZsG virus infection Nat Commun. 2019 Jan 17;10(1):285
Huh7 cells 0.2 µM (IC50) 24 hours Inhibits SKI-1/S1P protease activity, thereby blocking GNPTAB maturation Nat Commun. 2019 Jan 17;10(1):285
Rat inner medullary collecting duct (IMCD) cells 10 µM 24 hours PF-429242 inhibited AVP-induced increase in V2R expression and reduced medium sPRR content JCI Insight. 2019 Apr 4;4(7):e124174
Huh-7.5.1 cells 10 µM 24 hours Inhibition of SKI-1/S1P activity, blocking nuclear accumulation of SREBP-1 PLoS Pathog. 2012 Jan;8(1):e1002468
Mouse cortical collecting duct cell line (mpkCCD) 10 µM 24 hours To investigate the effect of S1P inhibition on Ang II-induced ENaC activity, results showed that PF-429242 blocked Ang II-induced ENaC activity, and this effect was reversed by sPRR-His supplementation. Hypertension. 2021 Feb;77(2):405-416
Differentiated 3T3 cells 10 µM 24 hours To investigate the effect of PF429242 on insulin signaling, results showed that PF429242 inhibited endogenous sPRR production, leading to reduced glucose uptake, which was partially restored by sPRR-His supplementation. JCI Insight. 2020 Apr 9;5(7):e128061
U87 cells 10 µM 24 hours To verify the inhibitory effect of PF-429242 on SREBP activity, results showed that PF-429242 could inhibit the expression of SREBP target genes J Biol Chem. 2016 Aug 12;291(33):17001-8
HeLa cells 10 µM 24 hours To verify the inhibitory effect of PF-429242 on SREBP activity, results showed that PF-429242 could inhibit the expression of SREBP target genes J Biol Chem. 2016 Aug 12;291(33):17001-8
Oligodendrocyte precursor cells (OPCs) 1-3 µM 3 days Preventing SREBP processing inhibited process growth and reduced the expression level of myelin basic protein (MBP) J Neurochem. 2017 Jan;140(1):53-67
293T cells 1, 10, 30 µM 36 hours To evaluate the inhibitory effect of PF-429242 on LCMV and LASV GPC cleavage. Results showed that PF-429242 effectively inhibited the cleavage of LCMV and LASV GPC but had no effect on GPCf. J Virol. 2011 Jan;85(2):795-803
BHK-21 baby hamster kidney fibroblast cells 20 µM 48 hours To test the inhibitory effect of PF-429242 on LCMV viral replication ACS Biomater Sci Eng. 2015 Nov 9;1(11):1050-1054
BHK-21 cells 0, 1, 10, 30 µM 48 hours To evaluate the inhibitory effect of PF-429242 on LCMV replication. Results showed that PF-429242 significantly inhibited LCMV replication but had a weaker effect on rLCMV-GPCf. J Virol. 2011 Jan;85(2):795-803
PLC5 cells 10 µM 6 hours Inhibition of S1P enhanced the anticancer activity of GSK343 Am J Cancer Res. 2019 Oct 1;9(10):2120-2139
HepG2 cells 10 µM 6 hours Inhibition of S1P enhanced the anticancer activity of GSK343 Am J Cancer Res. 2019 Oct 1;9(10):2120-2139
MEFs cells 10 µM 60 hours To verify the effect of PF-429242 on cell viability, results showed that PF-429242 had a minor effect on cell viability J Biol Chem. 2016 Aug 12;291(33):17001-8
RPE cells 10 µM 60 hours To verify the effect of PF-429242 on cell viability, results showed that PF-429242 had a minor effect on cell viability J Biol Chem. 2016 Aug 12;291(33):17001-8
U2OS cells 10 µM 60 hours To verify the effect of PF-429242 on cell viability, results showed that PF-429242 had a minor effect on cell viability J Biol Chem. 2016 Aug 12;291(33):17001-8
SH-SY5Y cells 10 µM 60 hours To verify the effect of PF-429242 on cell viability, results showed that PF-429242 had a minor effect on cell viability J Biol Chem. 2016 Aug 12;291(33):17001-8
Mouse peritoneal macrophages 200, 100, 50, 25, 12.5, and 6.25 µM 72 hours To evaluate the toxicity of PF-429242 against mammalian cells. Results showed that PF-429242 had low toxicity against macrophages with a CC50 value of 189.07 μM. Front Microbiol. 2021 Jan 28;12:583834
Leishmania infantum promastigotes 100, 50, 10, 5, 1, 0.5, 0.1, and 0.01 µM 72 hours To evaluate the antileishmanial effect of PF-429242 against L. infantum promastigotes. Results showed that PF-429242 had good activity against promastigotes with an IC50 value of 2.78 μM. Front Microbiol. 2021 Jan 28;12:583834
Leishmania amazonensis promastigotes 0–128 µM 72 hours To evaluate the leishmanicidal activity of PF-429242 against wild-type and simvastatin-resistant strains. Results showed that the EC50 for PF-429242 was 21.50 μM in LaSimR compared to 10.17 μM in wild-type, indicating cross-resistance in the resistant strain. Microorganisms. 2022 Feb 9;10(2):398

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NPG mice HepG2 tumor xenograft model Intravenous injection 20 mg/kg Twice weekly for 4 weeks PF-429242 inhibited HepG2 tumor growth in vivo Am J Cancer Res. 2023 Sep 15;13(9):4125-4144
C57/BL6 mice Wild-type mice Subcutaneous injection 20 mg/kg/day For 4 days PF-429242 treatment caused polyuria and hypoosmotic urine in mice and reduced renal V2R and AQP2 expression JCI Insight. 2019 Apr 4;4(7):e124174
B6129SF1/J mice Ang II-induced hypertension model Subcutaneous implantation via minipump 20 mg/kg/day Continuous for 6 days To evaluate the effect of PF-429242 on Ang II-induced hypertension, results showed that S1P inhibition significantly attenuated Ang II-induced hypertension, accompanied by suppressed urinary and renal medullary renin levels and reduced expression of renal medullary α-ENaC. Hypertension. 2021 Feb;77(2):405-416
C57/BL6 mice Diet-induced obesity model Subcutaneous injection 20 mg/kg/day Once daily for 2 weeks To investigate the effect of PF429242 on glucose metabolism, results showed that PF429242 significantly increased blood glucose and insulin levels and worsened glucose tolerance and insulin tolerance, which were corrected by sPRR-His supplementation. JCI Insight. 2020 Apr 9;5(7):e128061

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.07mL

0.41mL

0.21mL

10.36mL

2.07mL

1.04mL

20.73mL

4.15mL

2.07mL

References

 

Historical Records

Categories